
    
      PRIMARY OBJECTIVES:

      I. To determine safety of intravenous ascorbic acid in combination with fluorouracil,
      irinotecan hydrochloride, leucovorin calcium, and oxaliplatin (FOLFIRINOX) as defined by
      Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 in patients with advanced
      pancreatic cancer.

      SECONDARY OBJECTIVES:

      I. To test feasibility of collecting quality of life (QOL), patient reported outcomes (PRO)
      data and correlative studies on patients with advanced pancreatic cancer.
    
  